Takeda, Merck Diabetes Drug Combo Shown To Lower Blood Sugar
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's Actos (pioglitazone) and Merck's Januvia (sitagliptin) have shown in a study to be effective when used with insulin therapy to lower blood sugar in type 2 diabetics. Data from two clinical trials on lowering blood sugar showed a 2.4 percent reduction in a key measure of average blood glucose level over a two- to three-month period. The lowering of A1C levels from 8 percent to 12 percent to a relatively safe level of 7 percent or less was considered statistically significant. The trials combined Merck's new-generation drug with Takeda's older class of drug. (Click here for more